Cardiac surgery
Drug research and approvals for cardiac surgery: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 524 studies of cardiac surgery are recruiting on ClinicalTrials.gov, Health Canada has authorized 23 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 524
- Trials authorized in Canada: 23
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 524 recruiting on ClinicalTrials.gov ↗- Randomized Evaluation of Operating Room Extubation After Cardiac SurgeryNCT07757880 · Not applicable · Massachusetts General Hospital · starts Nov 9, 2026
- Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass SurgeryNCT07898215 · Not reported · Adiyaman University · starts Nov 4, 2026
- Continuous Glucose Monitoring in Patients Undergoing Cardiopulmonary BypassNCT06861881 · Not applicable · Wake Forest University Health Sciences · starts Nov 3, 2026
- BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac RehabilitationNCT07741396 · Not applicable · University of Illinois Chicago · starts Nov 2, 2026
- Hemodynamic Evaluation and Assessment of DIRECT myocaRdial and Sublingual Capillary Perfusion in Thoracic Surgery…NCT07135700 · Not reported · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · starts Nov 2, 2026
- Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in KidsNCT06882772 · Phase 1 / Phase 2 · University of Nebraska · starts Nov 1, 2026
- Cardiac Cycle Efficiency and Vasoactive-Inotropic Support After Cardiac SurgeryNCT07926360 · Not reported · Bursa City Hospital · starts Nov 1, 2026
- A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery…NCT07357675 · Phase 3 · EBI Anti Sepsis BV · starts Oct 29, 2026
- The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac SurgeryNCT07224711 · Phase 4 · Vanderbilt University Medical Center · starts Oct 26, 2026
- PRECISE-AFMR I: Transcatheter Mitral Valve Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation in Patients…NCT07741253 · Not applicable · China National Center for Cardiovascular Diseases · starts Oct 25, 2026
Trials Authorized in Canada
The 10 newest of 23; search them all in Canada trials| Feb 7, 2025 | Auto-plts: the effectiveness of autologous, cold-stored platelets collected 7-10 days before cardi-ac surgery for avoidance of allogeneic transfusions: a…AUTOLOGOUS COLD-STORED APHERESIS PLATELETS | DR. KEYVAN KARKOUTI | Ongoing |
| Jan 22, 2025 | Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (atenativ) in heparin-resistant…ATENATIV | OCTAPHARMA AG | Pending |
| Apr 12, 2024 | A phase 2b, randomized, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy on renal function, and safety, of…RMC-035 | GUARD THERAPEUTICS INTERNATIONAL AB | Ongoing |
| Apr 11, 2024 | A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of tin816 in…TIN816 | Novartis Pharmaceuticals Corporation | Ongoing |
| Feb 8, 2023 | A clinical comparison of cold-stored and room temperaturestored allogeneic platelet transfusions in bleeding adult cardiac surgery patients ¿ a randomized…COLD-STORED PLATELETS | DR. KEYVAN KARKOUTI | Pending |
| Dec 14, 2022 | Artemis: ravulizumab to protect patients with chronic kidney disease (ckd) from cardiac surgery associated acute kidney injury (csa-aki) and subsequent major…ULTOMIRIS | AstraZeneca Pharmaceuticals LP | Ongoing |
| Jun 23, 2022 | Factor replacement in surgery - four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgical patients (¿fares-ii¿ study)OCTAPLEX | OCTAPHARMA AG | Ongoing |
| Jan 11, 2022 | A phase 2, randomized, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of rmc-035 in subjects at…RMC-035 (RECOMBINANT HUMAN ALPHA-1-MICROGLOBULIN, ROSGARD, B125) | GUARD THERAPEUTICS INTERNATIONAL AB | Ongoing |
| Dec 29, 2021 | The combined use of inhaled epoprostenol and milrinone to prevent a separation of difficult extracorporeal circulation during heart surgery: double-blind…EPOPROSTENOL / MILRINONE | INSTITUT DE CARDIOLOGIE DE MTL | Pending |
| Jun 28, 2021 | A phase 2, double-blind, randomized, placebo-controlled study to evaluate the effect of rbt-1 on preconditioning response biomarkers in subjects undergoing…RBT-1 (IRON SUCROSE / STANNOUS PROTOPORPHYRIN) | RENIBUS THERAPEUTICS, INC. | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 8, 2022 | Nitric Oxideto selectively reduce pulmonary arterial pressures in patients at elevated risk for developing hemodynamically unstable pulmonary… | Keenova Therapeutics Ireland Limited | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 1, 2010 | Brinavessvernakalant hydrochloride | Advanz Pharma Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA